U042 Tackling Trichophyton Indotineae: A New Frontier in Antifungal Resistance
DESCRIPTION
This session explores the emergence of Trichophyton indotineae, a highly transmissible and antifungal-resistant dermatophyte causing widespread treatment challenges. Participants will review its epidemiology, clinical presentation, diagnostic pitfalls, and resistance mechanisms. The session will also cover evidence-based management strategies and antifungal stewardship principles. Designed for dermatologists, this talk aims to enhance recognition, improve treatment outcomes, and curb further spread of this emerging pathogen.
LEARNING OBJECTIVES
Describe the emergence, global spread, and clinical presentation of Trichophyton indotineae, including its differentiation from other dermatophyte infections.
Identify current diagnostic approaches and treatment limitations associated with T. indotineae, emphasizing its resistance to commonly used antifungals such as terbinafine.
Formulate appropriate management plans for patients infected with T. indotineae, including updated treatment protocols, antifungal stewardship, and infection control practices.
DIRECTOR
Rachel Kang, MD, FAAD
SPEAKERS
Avrom Caplan, MD, FAAD
Abigail Elizabeth Cline, MD, PhD, FAAD
DISCLOSURES
Avrom Caplan, MD, FAAD
Novartis – Consultant (1099 relationship)(Fees); Priovant Therapeutics – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding);
Abigail Elizabeth Cline, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Rachel Kang, MD, FAAD
No financial relationships exist with ineligible companies.